Modifiedmedical mutual - ohioPolicy AHS - G2173

Gamma-glutamyl Transferase Testing in Adults

Customize your policy alerts

Sign up for medical mutual - ohio Policy AHS - G2173 alerts

Get alerted when Policy AHS - G2173 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical coverage criteria for serum GGT testing in individuals aged 18 and older, specifying indications, frequency limits, and situations that do not meet coverage. It applies to providers and claims for Medical Mutual - Ohio members.

Policy Summary

Payermedical mutual - ohio

PolicyGamma-glutamyl Transferase Testing in Adults

Policy CodePolicy AHS - G2173

Change TypeMaterial revision — coverage criteria text updated

Effective DateFeb 1, 2026

Last ReviewSep 4, 2025

Next Review DateSep 4, 2025

Key ActionOrder serum GGT only for adults meeting listed clinical indications and no more than once every two weeks.

SourceLink

POLICY UPDATE CHANGES

Added 'of the digestive system.' to CC2.e., now reads: 'e) For individuals with primary or secondary malignant neoplasms of the digestive system.'

82977CPT code listed for GGT

>= 18age applicability

every 2 weeksmax frequency (indicated)

not covered

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Modifiedmedical mutual - ohioPolicy AHS - G2173

Gamma-glutamyl Transferase Testing in Adults

Customize your policy alerts

Sign up for medical mutual - ohio Policy AHS - G2173 alerts

Get alerted when Policy AHS - G2173 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payermedical mutual - ohio

PolicyGamma-glutamyl Transferase Testing in Adults

Policy CodePolicy AHS - G2173

Change TypeMaterial revision — coverage criteria text updated

Effective DateFeb 1, 2026

Last ReviewSep 4, 2025

Next Review DateSep 4, 2025

Key ActionOrder serum GGT only for adults meeting listed clinical indications and no more than once every two weeks.

SourceLink

POLICY UPDATE CHANGES

Added 'of the digestive system.' to CC2.e., now reads: 'e) For individuals with primary or secondary malignant neoplasms of the digestive system.'

82977CPT code listed for GGT

>= 18age applicability

every 2 weeksmax frequency (indicated)

not covered

not covered: asymptomatic screening

multiplecovered indications

09/04/2025Last review

Coverage Criteria for Serum GGT Testing

Indications meeting coverage

Covered when ALL of the following are met for individuals aged 18 or older:

Primary coverage rule

Covered indications list: a) Elevated alkaline phosphatase activity; OR b) Chronic alcohol use; OR c) Long-term drug therapy with potential for liver toxicity; OR d) Exposure to hepatotoxins; OR e) Viral hepatitis, amoebiasis, tuberculosis, psittacosis, or similar infections causing hepatic injury; OR f) Primary or secondary malignant neoplasms of the digestive system; OR g) Diabetes mellitus; OR h) Malnutrition; OR i) Disorders of iron and mineral metabolism; OR j) Sarcoidosis; OR k) Amyloidosis; OR l) Lupus; OR m) Hypertension; OR n) Gastrointestinal disease; OR o) Pancreatic disease; OR p) To assess liver function subsequent to liver transplantation.

Not covered

Asymptomatic screening not covered: Serum GGT testing during a wellness visit or general exam without abnormal findings does not meet coverage criteria.

This policy applies only to adults. Individuals under 18 years of age are excluded from the coverage criteria described herein; the criteria apply to individuals 18 years of age or older only. Additionally, serum GGT testing performed during a wellness visit or general exam for an asymptomatic individual without abnormal findings does not meet coverage criteria and is considered not medically necessary.

If there is a conflict between this policy and an applicable government policy (for example, Medicare Local Coverage Determinations, National Coverage Determinations, or state Medicaid coverage), the applicable government policy will govern the coverage determination for that member.

Serum GGT testing performed during a wellness visit or general exam for an asymptomatic individual without abnormal findings is considered not medically necessary and does not meet coverage criteria.

Indications Where Testing Is Covered

Elevated alkaline phosphatase activity

Elevated alkaline phosphatase activity: Serum GGT testing to evaluate an elevated alkaline phosphatase activity.no more than once every two weeks

Meets coverage criteria when performed no more than once every two weeks.

Assessment for liver injury, function, and/or disease when at least one listed condition is present

Assessment for liver injury, function, and/or disease

a): Chronic alcohol use.
b):

Situations That Do Not Meet Coverage

GGT testing for asymptomatic individuals during wellness visits or general physical examinations without abnormal findings is not covered. Such testing does not meet the policy's coverage criteria and is at risk for denial.

Professional guideline guidance indicates that GGT should not be used as a screening test for underlying liver disease in the absence of other abnormal liver chemistries. Given its lack of specificity, GGT is recommended as a confirmatory or second-line test (for example, to confirm hepatic origin of an isolated alkaline phosphatase elevation) rather than as a standalone population screening test.

Laboratory-developed tests (LDTs) for GGT are regulated under CLIA as high-complexity tests and must be validated and performed in-house by the reporting laboratory. FDA clearance or approval is not currently required for clinical use of LDTs, but CLIA/CMS regulatory requirements apply.

Applicable Procedure Codes

Applicable CPT CodesCPT

82977

Glutamyltransferase, gamma (GGT)

Provider Actions and Documentation Requirements

Prior Authorization

Prior authorization — none stated

No explicit prior authorization requirement is stated in this policy; coverage is determined by whether the clinical indications and frequency limits in the policy are met for the member at the time of the request.

Prior Authorization

Prior authorization: guidelines treat GGT as second-line/confirmatory

The policy does not specify prior authorization rules here; professional guidelines summarized in the policy describe GGT as a second-line or confirmatory test rather than a broad screening test.

CAG: GGT may be used as a second-line biochemical test when at least one liver screening test is abnormal.

Prior Authorization

Prior authorization — CPT 82977

Testing Frequency Limits

inv-30: Serum GGT frequency limit — no more than once every two weeks.

Frequency limitSerum GGT testing covered no more than once every two weeks for indicated uses.

Applies toIndividuals aged 18 years and older.

Context of useSpecifically noted for individuals with elevated alkaline phosphatase activity and other listed clinical indications.

inv-31: No explicit additional frequency limits provided in this excerpt.

Explicit frequency limitsNo additional explicit frequency limits are provided in the cited guideline excerpts.

Guideline contextCAG and ACG discuss testing indications and roles (second-line/confirmatory) but do not specify alternative frequency rules in this excerpt.

Ordering Requirements

Note

Ordering should be indication-based; no provider-type restriction

Order GGT based on the clinical indications listed in the policy; the policy does not impose a limitation on the provider type who may order the test.

Ensure the order documents the matching covered indication.

Note

Order GGT to confirm hepatic origin or as second-line test

Order GGT when needed to confirm hepatic origin of an isolated ALP elevation or when an initial abnormal liver screening test indicates second-line testing.

CAG: perform GGT when at least one liver screening test is abnormal as part of further biochemical testing.

Note

Align GGT orders with initial liver workup

Include GGT as part of the initial liver disease workup alongside bilirubin, albumin, ALT, ALP and a full blood count when clinically indicated.

Background and Rationale

Gamma-glutamyl transferase (GGT) is a cell-membrane enzyme present in multiple tissues; its serum measurement is commonly used as a marker of hepatic dysfunction, biliary disease, and alcohol-related liver injury. GGT is frequently ordered alongside other liver enzymes (e.g., ALT, AST, alkaline phosphatase) to help confirm hepatic origin of an elevated alkaline phosphatase or as part of the initial evaluation for suspected liver disease.

Because GGT is not specific to the liver and may be elevated in a variety of non-hepatic conditions and with certain medications, interpretation should be made in the clinical context and together with other liver chemistries and diagnostic information.

inv-21: Definition — GGT (Gamma-glutamyl transferase) enzyme description.

DefinitionGGT (Gamma-glutamyl transferase) is an enzyme present in cell membranes of many tissues (heart, brain, kidneys, bile duct, spleen, gallbladder) and has a half-life of about 14–26 days.

Also known asGamma-glutamyl transpeptidase (GGTP).

Clinical roleTraditionally used as a serum marker for liver dysfunction, bile duct disease, and alcohol consumption.

Policy Summary

Payermedical mutual - ohio

PolicyGamma-glutamyl Transferase Testing in Adults

Policy CodePolicy AHS - G2173

Change TypeMaterial revision — coverage criteria text updated

Effective DateFeb 1, 2026

Last ReviewSep 4, 2025

Next Review DateSep 4, 2025

Key ActionOrder serum GGT only for adults meeting listed clinical indications and no more than once every two weeks.

SourceLink

On This Page

Long-term drug therapy known to have potential for causing liver toxicity.

c): Exposure to hepatotoxins.

d): Viral hepatitis, amoebiasis, tuberculosis, psittacosis, or similar infections that may cause hepatic injury.

e): Primary or secondary malignant neoplasms of the digestive system.

f): Diabetes mellitus.

h): Disorders of iron and mineral metabolism.

m): Gastrointestinal disease.

n): Pancreatic disease.

o): To assess liver function subsequent to liver transplantation.

Confirmation of hepatic origin for isolated alkaline phosphatase elevation; further evaluation of abnormal liver screening tests

Confirmation and further evaluation: Use of GGT to confirm hepatic origin of isolated alkaline phosphatase elevation and as part of further evaluation when liver screening tests are abnormal.

ACG recommends repeating the liver panel and/or using GGT to confirm hepatic origin; CAG recommends GGT, albumin, bilirubin and PT/INR when at least one liver screening test is abnormal; BSG recommends including GGT in initial investigation for potential liver disease.

Identification of recent heavy alcohol use and risk for alcohol withdrawal

Identification of recent heavy alcohol use: Measurement of GGT (with ALT) to identify recent heavy alcohol use and risk for alcohol withdrawal, per ASAM guidance.

GGT may be used as a marker of heavy alcohol consumption but is not diagnostic alone.

Risk stratification or research biomarker

Risk stratification / research contexts: Use of GGT as a risk stratification or research biomarker where associations have been reported with metabolic syndrome, cardiovascular disease, stroke, type 2 diabetes, neurodegenerative disease, hepatocellular carcinoma risk after HCV, oral cancer, and other prognostic assessments; clinical utility varies by condition and context.

These uses reflect observational associations and may be appropriate in research or specialized prognostic assessments rather than routine screening.

Assessment of recent heavy alcohol use; part of initial evaluation for potential liver disease (with bilirubin, albumin, ALT, ALP and FBC)

Assessment of recent heavy alcohol use as part of initial liver evaluation: Use of GGT together with bilirubin, albumin, ALT, ALP and full blood count as part of the initial evaluation for potential liver disease and to assess recent heavy alcohol use.

ASAM recommends GGT and ALT to identify recent heavy alcohol use; BSG recommends inclusion of GGT in the initial investigation; document other tests as appropriate.

GGT testing is reported under CPT code 82977; follow any payer-specific prior authorization procedures that apply to that code.

82977 — Glutamyltransferase, gamma (GGT)

Note

Verify indication and member benefits

Ensure documentation supports the clinical indication for testing and the member's benefit coverage at the time of the request.

Verify member benefits and that one of the covered indications applies before ordering.

Billing Rule

Adhere to frequency limits

Order frequency must align with policy limits for covered indications (no more than once every two weeks when indicated).

Do not order serial GGT testing more frequently than the policy frequency limit for covered uses.

Documentation Required

Laboratory regulatory note for LDTs

If using a laboratory-developed test (LDT), ensure the test is performed and validated in accordance with CLIA/regulatory expectations as applicable to the performing laboratory.

Labs must validate and perform LDTs in-house under CLIA; FDA clearance is not required for LDTs.

Documentation Required

Document the covered clinical indication

Document the clinical indication in the medical record and on the claim — the record must show one of the policy-listed indications (for example, elevated ALP, chronic alcohol use, long‑term hepatotoxic drug therapy, exposure to hepatotoxins, viral hepatitis, digestive system malignancy, diabetes, malnutrition, iron metabolism disorders, sarcoidosis, amyloidosis, lupus, hypertension, GI or pancreatic disease, or post‑transplant monitoring).

Include specific clinical rationale that matches a covered indication before submitting the claim.
Ensure timing of testing is consistent with frequency limits when applicable.

Note

Use GGT to confirm hepatic origin of isolated ALP elevation

When alkaline phosphatase (ALP) is elevated but AST/ALT and bilirubin are normal, use GGT to confirm hepatic origin; if GGT is elevated, consider further evaluation such as liver ultrasound per clinical judgment.

ACG: repeat the panel and use GGT to confirm hepatic origin of isolated ALP elevation.
BSG: include GGT in initial investigation and proceed with additional evaluation as indicated.

Note

Order GGT with comprehensive liver panel and FBC

As part of initial investigation for potential liver disease, include bilirubin, albumin, ALT, ALP and GGT plus a full blood count if not done within the prior 12 months.

CAG: when at least one liver screening test is abnormal, obtain GGT, albumin, bilirubin and PT/INR as part of further evaluation.
BSG: initial investigation should include bilirubin, albumin, ALT, ALP and GGT with a full blood count.

Denial Risk

Denial risk — asymptomatic screening

Claims for serum GGT testing submitted for asymptomatic individuals during wellness visits or general exams without abnormal findings do not meet coverage criteria and are at risk for denial.

Do not submit claims for GGT as part of routine asymptomatic screening.

Denial Risk

Do not use GGT alone for screening

GGT is not specific for liver disease and should not be used alone as a screening test; interpret GGT results in the context of other liver chemistries and clinical findings.

ACG: GGT should not be used as a screening test in the absence of other abnormal liver chemistries.

Note

Government policy precedence

If this policy conflicts with an applicable government policy (e.g., Medicare LCD/NCD or state Medicaid), the government policy governs coverage determinations; follow the government policy in such cases.

Prior authorization noteAny payer-specific authorization requirements for CPT code 82977 must still be followed.

inv-32: Frequency limits placeholder (no chunk indices in source).

PlaceholderNo additional frequency-limit data available in source; refer to policy frequency (once every two weeks) and payer rules as applicable.

ActionIf local lab or payer imposes different limits, follow those requirements.

DocumentationEnsure clinical indication and timing documented to support repeat testing within allowed interval.

BSG: initial investigation should include GGT with other liver tests and FBC.
Ensure documentation of these concurrent tests supports the GGT order.

inv-22: Definition — GGT is not specific for liver disease and should not be used alone as a screening test.

SpecificityGGT is not specific for liver disease and should not be used alone as a screening test for underlying liver disease in the absence of other abnormal liver chemistries.

Guideline recommendationACG explicitly states GGT's lack of specificity and advises against its use as a standalone screening test.

ImplicationInterpret GGT results in conjunction with other liver chemistries (ALT, AST, ALP, bilirubin).

inv-23: Definition — GGT measured to assess hepatic function, cholestasis, and as a marker of heavy alcohol consumption; recommended with ALP and other liver tests.

Primary usesMeasured to assess hepatic function, detect cholestasis, and as a marker of heavy alcohol consumption.

Recommended testing contextACG, CAG and BSG recommend GGT be used with ALP and other liver tests (albumin, bilirubin, ALT) to confirm hepatic origin of ALP elevation or as part of initial/second-line evaluation of abnormal liver tests.

Alcohol assessmentASAM recommends GGT (with ALT) to identify recent heavy alcohol use and risk for alcohol withdrawal.